| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CXCL12; SDF1; SDF1A; SDF1B; Stromal cell-derived factor 1; SDF-1; hSDF-1; C-X-C motif chemokine 12; Intercrine reduced in hepatomas; IRH; hIRH; Pre-B cell growth-stimulating factor; PBSF |
| Entrez GeneID | 6387 |
| WB Predicted band size | Calculated MW: 11 kDa; Observed MW: 11 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human SDF-1. AA range:44-93 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于SDF1(CXCL12)抗体的示例参考文献(注：以下文献为示例性质，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**: *"Neutralizing SDF1 Antibody Attenuates Pulmonary Fibrosis via Inhibition of Myofibroblast Differentiation"*
**作者**: Zhou Y, et al. (2020)
**摘要**: 研究通过中和性SDF1抗体阻断CXCL12/CXCR4信号通路，发现其显著抑制小鼠肺纤维化模型中肌成纤维细胞的活化，提示SDF1抗体在纤维化疾病中的治疗潜力。
2. **文献名称**: *"Targeting the SDF1/CXCR4 Axis with Monoclonal Antibodies Suppresses Breast Cancer Metastasis"*
**作者**: Smith J, et al. (2018)
**摘要**: 利用抗SDF1单克隆抗体抑制肿瘤微环境中CXCL12的活性，显著减少乳腺癌细胞向骨和肺的转移，证实SDF1抗体在抑制肿瘤转移中的作用。
3. **文献名称**: *"SDF1 Neutralizing Antibody Enhances Stem Cell Homing to Ischemic Myocardium"*
**作者**: Wang L, et al. (2019)
**摘要**: 在心肌缺血模型中，SDF1抗体通过竞争性结合内源性CXCL12.促进外源性干细胞的归巢和修复功能，为心血管再生治疗提供新策略。
4. **文献名称**: *"Therapeutic Potential of Anti-SDF1 Antibodies in HIV Infection"*
**作者**: Gupta R, et al. (2016)
**摘要**: 研究发现SDF1抗体可阻断CXCR4介导的HIV病毒进入T细胞，为开发基于抗体阻断趋化因子通路的抗病毒疗法提供依据。
---
**备注**：以上文献标题及内容为示例，实际研究需参考具体论文。建议通过PubMed、Web of Science等平台检索关键词(如“SDF1 antibody”、“CXCL12 neutralization”)获取最新文献。
The stromal cell-derived factor 1 (SDF1), also known as CXCL12. is a chemokine critical in regulating immune cell trafficking, embryonic development, and tissue homeostasis. It binds primarily to the CXCR4 receptor, with a secondary interaction with CXCR7. activating signaling pathways involved in cell migration, survival, and proliferation. The SDF1-CXCR4 axis plays pivotal roles in hematopoiesis, stem cell homing, angiogenesis, and inflammatory responses. Dysregulation of this pathway is implicated in pathological conditions, including cancer metastasis, chronic inflammation, and HIV infection, where the virus exploits CXCR4 for cellular entry.
SDF1 antibodies are tools designed to target either the chemokine or its receptors, enabling research into modulating this pathway. Neutralizing antibodies against SDF1 or CXCR4 can block ligand-receptor interactions, offering potential therapeutic strategies. For instance, inhibiting SDF1/CXCR4 signaling may suppress tumor progression by disrupting the tumor microenvironment or preventing metastatic spread. In regenerative medicine, such antibodies help study stem cell mobilization for tissue repair. Additionally, they serve as diagnostic tools for detecting SDF1 expression in diseases. Despite their promise, challenges like specificity, off-target effects, and clinical translation require further optimization. Current research focuses on engineering antibody-based therapies, including bispecific antibodies or conjugates, to enhance efficacy in cancer immunotherapy and inflammatory disorders.
×
